214 related articles for article (PubMed ID: 29393896)
21. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
23. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
Choi SE; Weerasinghe SV; Pflum MK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6139-42. PubMed ID: 21889343
[TBL] [Abstract][Full Text] [Related]
24. The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors.
Cao F; Zwinderman MRH; Dekker FJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498635
[TBL] [Abstract][Full Text] [Related]
25. The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
Choi SE; Pflum MK
Bioorg Med Chem Lett; 2012 Dec; 22(23):7084-6. PubMed ID: 23089527
[TBL] [Abstract][Full Text] [Related]
26. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
27. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
[TBL] [Abstract][Full Text] [Related]
28. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
Guerrant W; Patil V; Canzoneri JC; Oyelere AK
J Med Chem; 2012 Feb; 55(4):1465-77. PubMed ID: 22260166
[TBL] [Abstract][Full Text] [Related]
29. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
30. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
Rossi C; Porcelloni M; D'Andrea P; Fincham CI; Ettorre A; Mauro S; Squarcia A; Bigioni M; Parlani M; Nardelli F; Binaschi M; Maggi CA; Fattori D
Bioorg Med Chem Lett; 2011 Apr; 21(8):2305-8. PubMed ID: 21420859
[TBL] [Abstract][Full Text] [Related]
31. Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
Liu Q; Zhang B; Wang Y; Wang X; Gou S
Eur J Med Chem; 2022 Feb; 229():114058. PubMed ID: 34954595
[TBL] [Abstract][Full Text] [Related]
32. Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.
Sun X; Hasanali ZS; Chen A; Zhang D; Liu X; Wang HG; Feith DJ; Loughran TP; Xu K
Br J Haematol; 2015 Feb; 168(3):371-83. PubMed ID: 25284154
[TBL] [Abstract][Full Text] [Related]
33. In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).
Tambunan US; Bramantya N; Parikesit AA
BMC Bioinformatics; 2011; 12 Suppl 13(Suppl 13):S23. PubMed ID: 22373132
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
[TBL] [Abstract][Full Text] [Related]
35. Phosphorus containing analogues of SAHA as inhibitors of HDACs.
Pun MD; Wu HH; Olatunji FP; Kesic BN; Peters JW; Berkman CE
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1315-1319. PubMed ID: 35514164
[TBL] [Abstract][Full Text] [Related]
36. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
Guan P; Wang L; Hou X; Wan Y; Xu W; Tang W; Fang H
Bioorg Med Chem; 2014 Nov; 22(21):5766-75. PubMed ID: 25311567
[TBL] [Abstract][Full Text] [Related]
37. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
Liu R; Wang J; Tang W; Fang H
Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
[TBL] [Abstract][Full Text] [Related]
39. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
40. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
